Publications by authors named "G Mellitzer"

Article Synopsis
  • Platinum-based drugs are standard treatments for gastric cancer, but resistance due to genetic mutations and metabolic changes limits their effectiveness.
  • The study presents RDC11, a new cycloruthenated compound that shows greater cytotoxicity and better tumor growth reduction compared to oxaliplatin.
  • RDC11 works by targeting glutathione metabolism, lowering cellular GSH levels, increasing reactive oxygen species, and triggering apoptosis, making it a promising alternative to combat resistance to current treatments.
View Article and Find Full Text PDF

The p53 protein plays a major role in cancer prevention, and over 50% of cancer diagnoses can be attributed to p53 malfunction. p53 incorporates a structural Zn site that is required for proper protein folding and function, and in many cases point mutations can result in loss of the Zn ion, destabilization of the tertiary structure, and eventual amyloid aggregation. Herein, we report a series of compounds designed to act as small molecule stabilizers of mutant p53, and feature Zn-binding fragments to chaperone Zn to the metal depleted site and restore wild-type (WT) function.

View Article and Find Full Text PDF

Background: Deconvoluting the heterogenous prognosis of Human Papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OSCC) is crucial for enhancing patient care, given its rapidly increasing incidence in western countries and the adverse side effects of OSCC treatments.

Methods: Transcriptomic data from HPV-positive OSCC samples were analyzed using unsupervised hierarchical clustering, and clinical relevance was evaluated using Kaplan-Meier analysis. HPV-positive OSCC cell line models were used in functional analyses and phenotypic assays to assess cell migration and invasion, response to cisplatin, and phagocytosis by macrophages .

View Article and Find Full Text PDF

The p53 protein, known as the 'guardian of the genome', plays an important role in cancer prevention. Unfortunately, p53 mutations result in compromised activity with over 50% of cancers resulting from point mutations to p53. There is considerable interest in mutant p53 reactivation, with the development of small-molecule reactivators showing promise.

View Article and Find Full Text PDF